BBA
IMNM icon

Baker Bros. Advisors’s Immunome IMNM Stock Holding History

Baker Bros. Advisors’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.17M Buy
+55,306
New +$1.18M 0.01% 79

Other funds holding IMNM

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

Baker Bros. Advisors's IMNM Position: Q2 2026 in Review

Baker Bros. Advisors opened a new position in Immunome (IMNM) in Q2 2026: 55,306 shares worth $1.17M. The stake represents 0.01% of the portfolio and ranks #79 among its holdings.

202 funds tracked by Wall St. Rank hold IMNM as of Q2 2026.

  • Baker Bros. Advisors held 55,306 shares of Immunome worth $1.17M as of Q2 2026.
  • Immunome was a new Baker Bros. Advisors position in Q2 2026.
  • Immunome made up 0.01% of Baker Bros. Advisors's portfolio in Q2 2026, its #79 holding.
  • 202 funds tracked by Wall St. Rank held Immunome as of Q2 2026.

Based on Baker Bros. Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.